Table 8 In vitro cytotoxic screening of 6a–n against A549 human lung cancer cells
Comp. | Validity (%) for sample concentrations (µg/mL) | IC50 (µg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 10 | 31.25 | 62.50 | 125 | 250 | 500 | 1000 | ||
6a | 100 | 98.6 | 89.1 | 79.2 | 75.9 | 70.3 | 30.7 | 20.8 | 14.4 | 185 |
6b | 100 | 95.7 | 86.9 | 85.8 | 83.5 | 77.8 | 68.2 | 35.2 | 36.3 | 338 |
6c | 100 | 92.4 | 80.7 | 59.8 | 54.2 | 31.3 | 25.1 | 19.7 | 17.7 | 85 |
6d | 100 | 97.9 | 92.6 | 77.2 | 67.3 | 49.02 | 24.6 | 20.4 | 19.4 | 117 |
6e | 100 | 95.4 | 90.3 | 87.5 | 81.7 | 71.1 | 50.7 | 33.2 | 28.8 | 276 |
6f | 100 | 91.3 | 89.8 | 86.2 | 83.2 | 67.3 | 46.6 | 38.6 | 25.4 | 230 |
6g | 100 | 94.5 | 90.1 | 86.9 | 73.5 | 68.9 | 63.1 | 18.4 | 14.4 | 308 |
6h | 100 | 89.5 | 80.9 | 78.98 | 75.8 | 63.5 | 37.9 | 33.03 | 30.3 | 192 |
6i | 100 | 96.6 | 91.9 | 89.4 | 78.1 | 76.3 | 67.9 | 53.3 | 49.4 | 801 |
6j | 100 | 95.6 | 87.8 | 76.6 | 68.2 | 54.00 | 31.3 | 29.2 | 28.3 | 175 |
6k | 100 | 90.8 | 80.8 | 75.98 | 70.6 | 55.4 | 39.8 | 28.7 | 23.0 | 203 |
6l | 100 | 85.04 | 72.2 | 58.1 | 53.6 | 43.1 | 34.0 | 30.3 | 27.9 | 95 |
6m | 100 | 91.5 | 81.8 | 67.6 | 65.9 | 62.7 | 58.7 | 54.1 | 49.8 | 830 |
6n | 100 | 93.3 | 83.6 | 67.9 | 64.2 | 52.7 | 43.2 | 39.1 | 36.3 | 159 |